Phase 1Completed
TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State
- Sponsor
- Tibotec Pharmaceuticals, Ireland (Industry)
- Enrollment
- 48 enrolled
- Conditions
- Hepatitis C Virus
- Interventions
- raltegravir; TMC435 + raltegravir; TMC435; TMC435 + efavirenz; TMC435; efavirenz
- Ages
- adults
- Registry
- NCT01241773
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the steady-state pharmacokinetics of efavirenz or raltegravir , and vice versa. Steady state is a term which means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Efavirenz and raltegravir are two antiretroviral drugs for treatment of human deficiency virus (HIV) infection. Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.
Primary outcomes
- Absorption of TMC435 following co-administration with efavirenz, and vice versa.
- Absorption of TMC435 following co-administration with raltegravir, and vice versa.
History
Last registry update
Primary completion
Registered
Started